Edgar Filing: FOLETTA MARK G - Form 4

FOI ETTA MADE C

| Form 4 | IAKK U | | | | | | | | | | |
|---|--------------------------------------|--------------------|--|---|---------------|---|------------|--|--|------------------------|--|
| December 06 | 1 |) STATES | SECUD | TTIES A | ND FY(| Ч ЦА В | JCE (| COMMISSION | | PPROVAL | |
| | UNITEL | J STATES | | | D.C. 205 | | NGE U | 2019119115510N | OMB Number: | 3235-0287 | |
| Check this if no long subject to Section 10 Form 4 or | er STATE | | | | | | | | Expires: January 31 2009 Estimated average burden hours per response 0.9 | | |
| Form 5 obligation may conti <i>See</i> Instru 1(b). | nue. Section 17 ction | (a) of the | Public Ut | ility Hold | | pany | Act of | e Act of 1934, f 1935 or Section 0 | n | | |
| (Print or Type R | esponses) | | | | | | | | | | |
| FOLETTA MARK G Syn | | | | 2. Issuer Name and Ticker or Trading Symbol Regulus Therapeutics Inc. [RGLS] | | | | 5. Relationship of Reporting Person(s) to Issuer | | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Check | | | | | k all applicable) | | | |
| | US THERAPE SCIENCE CEI | | (Month/D 12/04/20 | - | | | | X Director Officer (give below) | | Owner er (specify | |
| | Filed(Month/Day/Year) | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person | | | | | |
| SAN DIEGO |), CA 92121 | | | | | | | Form filed by M Person | | | |
| (City) | (State) | (Zip) | Table | e I - Non-D | erivative S | ecurit | ies Acq | uired, Disposed of | , or Beneficial | ly Owned | |
| 1.Title of Security (Instr. 3) | 2. Transaction Da (Month/Day/Year | r) Executio any | med n Date, if Day/Year) | Code | | sposed | of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Indirect Beneficial | |
| Common Stock | 12/04/2017 | | | A | 71,910 (1) | A | \$ 0.89 | 81,910 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: FOLETTA MARK G - Form 4

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transactio Code (Instr. 8) | 5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | ate | Secur | unt of rlying | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr |
|---|---|---|---|--|---|---------------------|--------------------|-------|--|---|--|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|--|---------------|-----------|---------|-------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| FOLETTA MARK G C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121 | Х | | | | | | |
| Signatures | | | | | | | |
| Christopher Aker, Attorney in Fact | 12/06/2017 | 7 | | | | | |
| **Signature of Reporting Person | Date | | | | | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of \$64,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.